Potential pathophysiological mechanisms in osteonecrosis of the jaw

Annals of the New York Academy of Sciences

Volumn 1218, Issue 1, 2011, Pages 62-79

  Landesberg, Regina ^a   Woo, Victoria ^b   Cremers, Serge ^c   Cozin, Matthew ^d   Marolt, Darja ^e   Vunjak Novakovic, Gordana ^e   Kousteni, Stavroula ^c   Raghavan, Srikala ^f  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b UNIVERSITY OF NEVADA   (United States)

^c Columbia University ^*  (United States)

^d Och Spine at New York Presbyterian Hospitals   (United States)

^e NONE   (United States)

^f New York Presbyterian Hospital   (United States)

Author keywords

Bisphosphonates; ONJ; Osteonecrosis; Pathophysiology

Indexed keywords

BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CASPASE 3; CORTICOSTEROID; CYCLOHEXIMIDE; NITROGEN; PAMIDRONIC ACID; PARATHYROID HORMONE; STAUROSPORINE; ZOLEDRONIC ACID;

ANGIOGENESIS; ARTICLE; AUTOIMMUNE DISEASE; BONE CELL; BONE TURNOVER; BREAST CANCER; CANCER CHEMOTHERAPY; CELL CULTURE; CELL MIGRATION; CELL PROLIFERATION; CRANIOFACIAL MORPHOLOGY; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG INHIBITION; ENZYME ACTIVITY; EPITHELIUM CELL; HUMAN; HYPERCOAGULABILITY; INCUBATION TIME; JAW OSTEONECROSIS; KERATINOCYTE; MEDICAL LITERATURE; NONHUMAN; OSTEOBLAST; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; RISK FACTOR; VASCULARIZATION; WOUND HEALING;

EID: 79551548081     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05835.x     Document Type: Article

References (103)

1. Major, P. 2002. The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy. Oncologist 7: 481-491.
2. Rosen, L.S. et al 2001. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 7: 377-387.
3. Saad, F. et al 2002. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J. Natl. Cancer Inst. 94: 1458-1468.
4. Van Poznak, C.H. 2002. The use of bisphosphonates in patients with breast cancer. Cancer Control 9: 480-489.
5. Marx, R.E. 2003. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J. Oral Maxillofac. Surg. 61: 1115-1117.
6. Migliorati, C.A. 2003. Bisphosphanates and oral cavity avascular bone necrosis. J. Clin. Oncol. 21: 4253-4254.
7. Wang, J., N.M. Goodger & M.A. Pogrel 2003. Osteonecrosis of the jaws associated with cancer chemotherapy. J. Oral. Maxillofac. Surg. 61: 1104-1107.
8. Pogrel, M.A. 2004. Bisphosphonates and bone necrosis. J. Oral. Maxillofac. Surg. 62: 391-392.
9. Ruggiero, S.L. et al 2004. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J. Oral. Maxillofac. Surg. 62: 527-534.
10. Marx, R.E. et al 2005. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J. Oral. Maxillofac. Surg. 63: 1567-1575.
11. Ruggiero, S.L. et al. American Association of Oral and Maxillofacial Surgeons. 2009. Position paper on bisphosphonate-related osteonecrosis of the jaws. J. Oral. Maxillofac. Surg. 67(Suppl. 5): 2-12.
12. Khosla, S. et al 2007. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J. Bone Miner. Res. 22: 1479-1491.
13. Kyle, R.A. et al 2007. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J. Clin. Oncol. 25: 2464-2472.
14. Ruggiero, S.L., J. Fantasia & E. Carlson. 2006. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral. Surg. Oral. Med. Oral. Pathol. Oral. Radiol. Endod. 102: 433-441.
15. Toshiyki T., H. Hiroshi, T. Toshitsugu., et al. 2010. Bisphosphonate-related osteonecrosis of the jaw: position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeons. J. Bone Miner. Metab. 28: 385-383.
16. Patel V., McLeod N.M.H., S.M. Rogers & P.A. Brennan 2010. Bisphosphonate osteonecrosis of the jaw-a literature review of UK policies versus international policies on bisphosphonates, risk factors and prevention. Br. J. Oral Maxillofac. Surg. In press.
17. Ruggiero S., T.B. Dodson, L.A. Assael, et al 2009. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw. Australian Endodontic. J. 35: 119-130.
18. Lugassy, G. et al 2004. Severe osteomyelitis of the jaw in long-term survivors of multiple myeloma: a new clinical entity. Am. J. Med. 117: 440-441.
19. Melo, M.D. & G. Obeid. 2005. Osteonecrosis of the maxilla in a patient with a history of bisphosphonate therapy. J. Can. Dent. Assoc. 71: 111-113.
20. Hansen, T. et al 2007. Actinomycosis of the jaws-histopathological study of 45 patients shows significant involvement in bisphosphonate-associated osteonecrosis and infected osteoradionecrosis. Virchows Arch. 451: 1009-1017.
21. Kos M., Brusco D., J. Kuebler & W. Engelke 2010. Clinical comparison of patients with osteonecrosis of the jaws, with and without a history of bisphosphonates administration. Int. J. Oral Maxillofac. Surg. 39: 1097-1102.
22. Hall, V. 2008. Actinomyces: gathering evidence of human colonization and infection. Anaerobe 14: 1-7.
23. Naik N.H. & T.A. Russo 2009. Bisphosphonate-related osteonecrosis of the jaw: the role of Actinomyces. CID 49: 1729-1732.
24. Kolenbrander, P.E. 2000. Oral microbial communities: biofilms, interactions, and genetic systems. Annu. Rev. Microbiol. 54: 413-437.
25. Chapurlat, R.D. et al 2007. Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study. J. Bone Miner. Res. 22: 1502-1509.
26. Stepan, J.J. et al 2007. Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis. Bone 41: 378-385.
27. Woo, S.B., J.W. Hellstein & J.R. Kalmar, Narrative 2006. [Corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann. Intern. Med. 144: 753-761.
28. Twiss, I.M., et al. 1994. Cytotoxic effects of pamidronate on monolayers of human intestinal epithelial (Caco-2) cells and its epithelial transport. J. Pharm. Sci. 83: 699-703.
29. Twiss, I.M. et al 1999. The effects of nitrogen-containing bisphosphonates on human epithelial (Caco-2) cells, an in vitro model for intestinal epithelium. J. Bone Miner. Res. 14: 784-791.
30. Wallace, J.L. et al 1999. N-bisphosphonates cause gastric epithelial injury independent of effects on the microcirculation. Aliment Pharmacol. Ther. 13: 1675-1682.
31. Suri, S. et al 2001. Nitrogen-containing bisphosphonates induce apoptosis of Caco-2 cells in vitro by inhibiting the mevalonate pathway: a model of bisphosphonate-induced gastrointestinal toxicity. Bone 29: 336-343.
32. Giraudo, E., M. Inoue & D. Hanahan. 2004. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J. Clin. Invest. 114: 623-633.
33. Perazella, M.A. 2003. Drug-induced renal failure: update on new medications and unique mechanisms of nephrotoxicity. Am. J. Med. Sci. 325: 349-362.
34. Montague, R., et al. 2004. Differential inhibition of invasion and proliferation by bisphosphonates: anti-metastatic potential of Zoledronic acid in prostate cancer. Eur. Urol. 46: 389-401; discussion 401-402.
35. Landesberg, R. et al 2008. Inhibition of oral mucosal cell wound healing by bisphosphonates. J. Oral. Maxillofac. Surg. 66: 839-847.
36. Leyvraz, S. et al 1992. Pharmacokinetics of pamidronate in patients with bone metastases. J. Natl. Cancer Inst. 84: 788-792.
37. Reid, I.R., M.J. Bolland & A.B. Grey. 2007. Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity Bone 41: 318-320.
38. King, L.E. & R. Vieth. 1996. Extraction and measurement of pamidronate from bone samples using automated pre-column derivatization, high-performance liquid chromatography and fluorescence detection. J. Chromatogr. B Biomed. Appl. 678: 325-330.
39. Hoggarth, C.R., R. Bennett & P.T. Daley-Yates. 1991. The pharmacokinetics and distribution of pamidronate for a range of doses in the mouse. Calcif. Tissue Int. 49: 416-420.
40. Bauss, F. & R.G. Russell. 2004. Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing. Osteoporos. Int. 15: 423-433.
41. Monkkonen, J., H.M. Koponen & P. Ylitalo. 1990. Comparison of the distribution of three bisphosphonates in mice. Pharmacol. Toxicol. 66: 294-298.
42. Usui, T. et al 1997. Pharmacokinetics of incadronate, a new bisphosphonate, in healthy volunteers and patients with malignancy-associated hypercalcemia. Int. J. Clin. Pharmacol. Ther. 35: 239-244.
43. Olsen, B.R., A.M. Reginato & W. Wang. 2000. Bone development. Annu. Rev. Cell Dev. Biol. 16: 191-220.
44. Karsenty, G. 2003. The complexities of skeletal biology. Nature 423: 316-318.
45. Declercq, H., et al. 2004. Isolation, proliferation and differentiation of osteoblastic cells to study cell/biomaterial interactions: comparison of different isolation techniques and source. Biomaterials 25: 757-768.
46. Declercq, H.A. et al 2005. Calcification as an indicator of osteoinductive capacity of biomaterials in osteoblastic cell cultures. Biomaterials 26: 4964-4974.
47. Siggelkow, H. et al 1999. Development of the osteoblast phenotype in primary human osteoblasts in culture: comparison with rat calvarial cells in osteoblast differentiation. J. Cell Biochem. 75: 22-35.
48. de Pollak, C. et al 1997. Age-related changes in bone formation, osteoblastic cell proliferation, and differentiation during postnatal osteogenesis in human calvaria. J. Cell Biochem. 64: 128-139.
49. Suttapreyasri, S. et al 2006. Expression of bone morphogenetic proteins in normal human intramembranous and endochondral bones. Int. J. Oral Maxillofac. Surg. 35: 444-452.
50. Stefanik D., J. Sarin, T. Lam, et al. 2008. Disparate osteogenic response of mandible and iliac crest bone marrow stromal cells to pamidronate. Oral Dis. 14: 465-471.
51. Everts V., W. Korper, D.C. Jansen, et al 1999. Functional heterogeneity of osteoclasts: matrix metalloproteinases participate in osteoclastic resorption of calvarial bone but not in resorption of long bone. FASEB J. 13: 1219-1230.
52. Everts V., W. Korper, A.J. Docherty & W. Beertsen 1999. Matrix metalloproteinase inhibitors block osteoclastic resorption of calvarial bone but not the resorption of long bone. Ann. N.Y. Acad. Sci. 878: 603-608.
53. Aghaloo T.L., A.L. Felsenfeld & S. Tetradis 2010. Osteonecrosis of the jaw in a patient on Denosumab. J. Oral Maxillofac. Surg. 68: 959-963.
54. Taylor K.H., L.S. Middlefell & K.D. Mizen 2010. Osteonecrosis of the jaws induced by anti-RANK ligand therapy. Br. J. Oral Surg. 48: 221-223.
55. Kapitola, J. & J. Zak 1998. Effect of pamidronate on bone blood flow in oophorectomized rats. Physiol. Res. 47: 237-240.
56. Marx, R.E. 1983. Osteoradionecrosis: a new concept of its pathophysiology. J. Oral Maxillofac. Surg. 41: 283-288.
57. Wood, J. et al 2002. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J. Pharmacol. Exp. Ther. 302: 1055-1061.
58. Bezzi, M. et al 2003. Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death: evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B/Akt. J. Biol. Chem. 278: 43603-43614.
59. Fournier, P. et al 2002. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res. 62: 6538-6544.
60. Hamma-Kourbali, Y. et al 2003. A novel non-containing-nitrogen bisphosphonate inhibits both in vitro and in vivo angiogenesis. Biochem. Biophys. Res. Comm. 310: 816-823.
61. Okamoto, T. et al 2002. Incadronate disodium inhibits advanced glycation end products-induced angiogenesis in vitro. Biochem. Biophys. Res. Comm. 297: 419-424.
62. Teronen, O. et al 1999. MMP inhibition and downregulation by bisphosphonates. Ann. N. Y. Acad. Sci. 878: 453-465.
63. Santini, D. et al 2002. Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin. Cancer Res. 8: 1080-1084.
64. Santini, D. et al 2003. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin. Cancer Res. 9: 2893-2897.
65. Santini, D. et al 2007. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin. Cancer Res. 13(15 Pt 1): 4482-4486.
66. Vincenzi, B. et al 2005. Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. J. Interferon. Cytokine Res. 25: 144-151.
67. Van Poznack, C. 2010. Osteonecrosis of the jaw and bevacizumab therapy. Breast Cancer Res. Treat. 122: 189-191.
68. Brem, H. & M. Tomic-Canic. 2007. Cellular and molecular basis of wound healing in diabetes.[comment]. J. Clin. Inv. 117: 1219-1222.
69. Falanga, V. 2005. Wound healing and its impairment in the diabetic foot. Lancet 366: 1736-1743.
70. Khamaisi, M. et al 2007. Possible association between diabetes and bisphosphonate-related jaw osteonecrosis. [see comment]. J. Clin. Endocrinol. Metabol. 92: 1172-1175.
71. Harper, P.G., C. Trask & R.L. Souhami. 1984. Avascular necrosis of bone caused by combination chemotherapy without corticosteroids. Br. Med. J. Clin. Res. Ed. 288: 267-268.
72. Marymont, J.V. & E.E. Kaufman. 1986. Osteonecrosis of bone associated with combination chemotherapy without corticosteroids. Clin. Orthopead. Rel. Res. 204: 150-153.
73. Sung, E.C. et al 2002. Osteonecrosis of the maxilla as a complication to chemotherapy: a case report. Spec. Care Dentist. 22: 142-146.
74. Jones, L.C. & D.S. Hungerford. 2004. Osteonecrosis: etiology, diagnosis, and treatment. Cur. Opin. Rheumatol. 16: 443-9.
75. Ortega, C. et al 2007. Osteonecrosis of the jaw in prostate cancer patients with bone metastases treated with zoledronate: a retrospective analysis. Acta. Oncologica. 46: 664-668.
76. Tosi, P. et al 2006. Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone. Blood 108: 3951-3952.
77. Van Den Wyngaert, T., M.T. Huizing & J.B. Vermorken. 2006. Bisphosphonates and osteonecrosis of the jaw: cause and effect or a post hoc fallacy? Ann. Oncol. 17: 1197-1204.
78. Bi Y., Y. Gao, D. Ehirchiou, et al 2010. Bisphosphonates cause osteonecrosis of the jaw-like disease in mice. Am. J. Pathol. 177: 280-290.
79. Roelofs, A.J. et al 2006. Molecular mechanisms of action of bisphosphonates: current status. Clin. Cancer Res. 12(20 Pt 2): 6222s-6230s.
80. Gober, H.J. et al 2003. Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J. Exp. Med. 197: 163-168.
81. Hewitt, R.E. et al 2005. The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins. Clin. Exp. Immunol. 139: 101-111.
82. Thompson, K. & M.J. Rogers. 2004. Statins prevent bisphosphonate-induced gamma, delta-T-cell proliferation and activation in vitro. J. Bone Miner. Res. 19: 278-288.
83. Kunzmann, V. et al 2000. Stimulation of gamma delta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 96: 384-392.
84. Kunzmann, V., E. Bauer & M. Wilhelm. 1999. Gamma/delta T-cell stimulation by pamidronate. N. Engl. J. Med. 340: 737-738.
85. Atsumi, T., Y. Kuroki & K. Yamano. 1989. A microangiographic study of idiopathic osteonecrosis of the femoral head. Clin. Orthop. Relat. Res. 246: 186-194.
86. Jones, J.P., Jr 1992. Intravascular coagulation and osteonecrosis. Clin. Orthop. Relat. Res. 277: 41-53.
87. Mankin, H.J. 1992. Nontraumatic necrosis of bone (osteonecrosis). N. Engl. J. Med. 326: 1473-1479.
88. Jones, J.P. 2001. Osteonecrosis. In Arthritis and Allied Conditions: A Textbook of Rheumatology. 14th ed. Lippincot Williams and Wilkins, Philadelphia, PA
89. Glueck, C.J. et al 1997. Heterozygosity for the Leiden mutation of the factor V gene, a common pathoetiology for osteonecrosis of the jaw, with thrombophilia augmented by exogenous estrogens. J. Lab. Clin. Med. 130: 540-543.
90. Glueck, C.J. et al 1994. Hypofibrinolysis: a common, major cause of osteonecrosis. Am. J. Hematol. 45: 156-166.
91. Glueck, C.J. et al 1995. Idiopathic osteonecrosis, hypofibrinolysis, high plasminogen activator inhibitor, high lipoprotein(a), and therapy with Stanozolol. Am. J. Hematol. 48: 213-220.
92. Glueck, C.J. et al 1997. Thrombophilia and hypofibrinolysis: pathophysiologies of osteonecrosis. Clin. Orthop. Relat. Res. 334: 43-56.
93. Glueck, C.J. et al 1993. Familial high plasminogen activator inhibitor with hypofibrinolysis, a new pathophysiologic cause of osteonecrosis? Thromb. Haemost. 69: 460-465.
94. Glueck, C.J. et al 1994. Familial idiopathic osteonecrosis mediated by familial hypofibrinolysis with high levels of plasminogen activator inhibitor. Thromb. Haemost. 71: 195-198.
95. Glueck, C.J. et al 1996. Thrombophilia, hypofibrinolysis, and alveolar osteonecrosis of the jaws. Oral. Surg. Oral. Med. Oral. Pathol. Oral. Radiol. Endod. 81: 557-566.
96. Glueck, C.J., R.A. Freiberg & P. Wang. 2008. Heritable thrombophilia-hypofibrinolysis and osteonecrosis of the femoral head. Clin. Orthop. Relat. Res. 466: 1034-1040.
97. Glueck C.J.F.R., R. Gruppo, A. Crawford, et al. 1997. Thrombophilia and hypofibrinolysis: reversible pathogenetic etiologies of osteonecrosis. In Osteonecrosis Etiology, Diagnosis and Treatment. Chapter 14, Publication of the American Association of Orthopedic Surgeons, Rosemont, IL James R. Urbaniak & John Paul Jones, Jr., Eds.
98. McMahon, R.E. et al 2004. Osteonecrosis: a multifactorial etiology. J. Oral Maxillofac. Surg. 62: 904-905.
99. Tanvetyanon T.S.P. 2006. Management of the adverse effects associated with intravenous bisphosphonates. Ann. Oncol. 17: 897-907.
100. Berruti, A. et al 2002. Metabolic effects of single-dose pamidronate administration in prostate cancer patients with bone metastases. Int. J. Biol. Markers. 17: 244-252.
101. Berruti, A.D.L. & M. Tucci 2001. Metabolic bone disease induced by prostate cancer. Rationale for the use of bisphosphonates. J. Urol. 166: 2023-2031.
102. Elder, G. 2002. Pathophysiology and recent advances in the management of renal osteodystrophy. J. Bone Miner. Res. 17: 2094-2105.
103. Ardine, M. et al 2006. Could the long-term persistence of low serum calcium levels and high serum parathyroid hormone levels during bisphosphonate treatment predispose metastatic breast cancer patients to undergo osteonecrosis of the jaw? Ann. Oncol. 17: 1336-1337.